Literature DB >> 25012915

Association between the MMP-9-1562 C>T polymorphism and the risk of stroke: a meta-analysis.

Zhen-Zhen Fan1, Zhao-Ming Ge, Hong-Bin Cai, Zhi-Yan Liu, Pei Liu, Hao-Yue Wang.   

Abstract

Matrix metalloproteinase (MMP)-9 so far is identified as extremely large and complicated MMP family member. Recently, dozens of studies have explored the association between a promoter polymorphism (-1562 C>T) in MMP-9 and stroke susceptibility. However, the conclusions of these studies still remain equivocal. Therefore, our current meta-analysis was conducted to investigate whether or not the MMP-9 promoter polymorphism is related to the risk of stroke. Electronic databases (PubMed, EMBASE, Web of Science, Cochrane Library and the Chinese Biomedical Literature Database) were searched to obtain all the available studies investigating this polymorphism and stroke from inception to October 2013. Overall and subgroup analyses were rigorously conducted after data extraction. Pooled odds ratio (OR) corresponding to 95 % confidence interval (CI) were estimated. The statistical analysis was performed using Review Manager 5.2. Totally, seven studies involving 1,624 cases and 1,525 controls were identified. The overall results suggested that there was no association of the C-1562T variant on stroke risk under the T allele versus C allele [OR T vs. C 0.98, 95 % CI (0.84, 1.15), P = 0.84], the dominant model [OR TT+TC vs. CC 0.95, 95 % CI (0.81, 1.13), P = 0.59], the recessive model [OR TT vs. TC+CC 1.55, 95 % CI (0.86, 2.81), P = 0.15], the homozygote comparison [OR TT vs. CC 1.48, 95 % CI (0.82, 2.68), P = 0.20] and the heterozygote comparison [OR TC vs. CC 0.93, 95 % CI (0.78, 1.10), P = 0.38]. In the subgroup analyses by ethnicity, age, stroke type and source of controls, no significant relations were observed in any genetic models. Our results indicated that MMP-9-1562 C>T polymorphism was not a risk factor for stroke. Further studies should focus on gene-gene and gene-environment interactions, and provide a more convincing explanation for this association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25012915     DOI: 10.1007/s11033-014-3564-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  29 in total

Review 1.  Matrix metalloproteinases (MMPs) in health and disease: an overview.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

2.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

Authors:  I M Loftus; A R Naylor; S Goodall; M Crowther; L Jones; P R Bell; M M Thompson
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

Review 3.  Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.

Authors:  S Ye
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

4.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis.

Authors:  B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

5.  Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage.

Authors:  B Zhang; S Dhillon; I Geary; W M Howell; F Iannotti; I N Day; S Ye
Journal:  Stroke       Date:  2001-09       Impact factor: 7.914

6.  Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.

Authors:  Carmel M McEniery; Kevin M O'Shaughnessy; Patrick Harnett; Asif Arshad; Sharon Wallace; Kaisa Maki-Petaja; Barry McDonnell; Mike J Ashby; John Brown; John R Cockcroft; Ian B Wilkinson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-05-18       Impact factor: 8.311

7.  Standard method for developing stroke registers in low-income and middle-income countries: experiences from a feasibility study of a stepwise approach to stroke surveillance (STEPS Stroke).

Authors:  T Truelsen; P U Heuschmann; R Bonita; G Arjundas; P Dalal; A Damasceno; D Nagaraja; A Ogunniyi; S Oveisgharan; K Radhakrishnan; V I Skvortsoya; V Stakhovskaya
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

8.  Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke.

Authors:  Helena Manso; Tiago Krug; João Sobral; Isabel Albergaria; Gisela Gaspar; José M Ferro; Sofia A Oliveira; Astrid M Vicente
Journal:  BMC Med Genet       Date:  2010-03-11       Impact factor: 2.103

9.  Endothelial nitric oxide (eNOS) gene G894T and VNTR polymorphisms are closely associated with the risk of ischemic stroke development for Asians: meta-analysis of epidemiological studies.

Authors:  Xiaolong Guo
Journal:  Mol Biol Rep       Date:  2014-02-27       Impact factor: 2.316

10.  A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia.

Authors:  Zezong Gu; Jiankun Cui; Stephen Brown; Rafael Fridman; Shahriar Mobashery; Alex Y Strongin; Stuart A Lipton
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.